Antidote's best-in-class clinical trial search engine will be featured across XpertPatient.com, an award-winning educational website, helping cancer patients better understand and seamlessly match to medical research opportunities.
MIAMI and CHATHAM, N.J., Feb. 7, 2023 /PRNewswire-PRWeb/ -- Antidote Technologies ("Antidote"), a digital patient engagement company that connects clinical trial sponsors and patients, and XpertPatient.com, an award-winning website that provides support to newly-diagnosed cancer patients, today announced a partnership to provide the XpertPatient.com community with access to Antidote Match™, a patient-friendly clinical trial search that currently powers clinical trial matching for 300+ patient organizations.
The addition of Antidote Match to XpertPatient.com will increase patient understanding of clinical trials and help build awareness of all of their treatment options, from those currently FDA-approved to those in the research stages. Together, we are ensuring that those on a cancer journey are informed about research opportunities, which will ultimately lead to increased participation, better quality clinical trial results, and new treatments coming to the market faster.
Antidote is currently powering clinical trial search across the treatment option pages of XpertPatient.com in three cancer centers, breast cancer, prostate cancer, and lung cancer, and will be added to the site's remaining ten cancer centers by the summer of 2023.
There are an estimated 18.1 million cancer cases around the world, and cancer is the second leading cause of death in the United States. For these patients, new and better treatment options are critical — but currently, only 8% of cancer patients are enrolled in treatment trials. As discussed in a recent podcast, Antidote and XpertPatient.com recognize the importance of providing educational materials about treatment options and clinical trial participation to those who have been diagnosed with cancer.
"Antidote is providing an easy-to-use clinical trial matching tool specific to each of XpertPatient.com's 13 online cancer centers. Our UX team has integrated the tool into a simple, yet rich, learning experience for our visitors," said Risa Arin, Founder and CEO of XpertPatient.com. "By joining forces, we are providing those new to cancer with a more holistic view of their options, building confidence and enabling them to be true partners to their doctors during treatment planning."
Importantly, Antidote and XpertPatient.com are also committed to ensuring that the individuals taking part in clinical trials are reflective of the real-world patient population. Clinical trials as a whole are often lacking in their representation of racial and ethnic minorities, and cancer trials have exhibited a clear tendency to be less diverse than the average patient population — which can have serious implications for communities of color. For example, the mortality rate for black women with breast cancer is 40% higher than that of white women. While there are many factors involved in statistics like this, creating more inclusive patient recruitment for clinical trials is one of the key ways to address these disparities.
"Providing patients with the ability to discover clinical trial opportunities is at the core of what Antidote does," said Laurent Schockmel, CEO of Antidote. "XpertPatient.com's strong presence in the cancer community makes them an ideal partner for Antidote, and we are delighted that they have selected our Match technology as an important resource for their communities."
A lack of enrollment is a major problem facing the entire medical research industry. By providing patients with a simple and streamlined way to find clinical trials for which they may be eligible, the partnership between Antidote and XpertPatient.com will serve to assist patients and advance the future of oncology breakthroughs.
About Antidote
Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive, diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.
About XpertPatient.com
XpertPatient.com is an award-winning, next-gen website empowering cancer patients to become "cancer smart" and to feel confident being true partners to their doctors and nurses. They are committed to helping new cancer patients understand their diagnosis and the differences between the latest oncological treatment options available. By guiding visitors through a personalized website experience, XpertPatient.com provides resources, educational material, and community for patients, making a complex and overwhelming life situation easier to navigate and understand. For more information, visit http://www.xpertpatient.com.
Media Contacts
Faith Brewitt
[email protected]
+1 603 686 0913
Lisa Conroy
Head of Communications, Antidote
[email protected]
+1 215 872 2917
Media Contact
Lisa Conroy, Antidote, 1 2158-72-2917, [email protected]
Faith Brewitt, XpertPatient, 603 686 0913, [email protected]
SOURCE Antidote
Share this article